ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,059.31
0.78%
Dow Jones
44,831.90
0.26%
US Dollar vs MXN
20.57299
-0.83%
Brent Oil
76.465
0.26%
Bitcoin
102,201.47
0.13%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Altimmune Inc (ALT) Cotización

Altimmune Inc

Altimmune Inc (ALT)

Analytica Limited
Altitude Group Plc
Alturas Minerals Corp
6.955
-0.045
( -0.64% )
Actualizado: 12:42:03
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
6.955
Postura de Compra
6.95
Postura de Venta
6.96
Volume Operado de la Acción
763,564
6.825 Rango del Día 7.00
5.275 Rango de 52 semanas 14.84
Capitalización de Mercado [m]
494.672M
Precio Anterior
7.00
Precio de Apertura
6.97
Hora
100
@
6.955
Última hora de negociación
12:42:18
Volumen financiero
US$ 5,277,949
Precio Promedio Ponderado
6.9123
Volumen promedio (3 m)
3,425,949
Acciones en circulación
71,124,625
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-5.60
Beneficio por acción (BPA)
-1.24
turnover
426k
Beneficio neto
-88.45M

Acerca de Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.altimmune.com
Sede
Wilmington, Delaware, USA
Fundado
-
Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was US$7. Over the last year, Altimmune shares have traded in a share price range of US$ 5.275 to US$ 14.84.

Altimmune currently has 71,124,625 shares in issue. The market capitalisation of Altimmune is US$497.87 million. Altimmune has a price to earnings ratio (PE ratio) of -5.60.

ALT Últimas noticias

Más noticias

Altimmune Added to Nasdaq Biotechnology Index

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology...

19 Diciembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

11 Diciembre 2024
Edgar (US Regulatory)

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...

02 Diciembre 2024
GlobeNewswire Inc.

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...

26 Noviembre 2024
GlobeNewswire Inc.

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide...

15 Noviembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

12 Noviembre 2024
Edgar (US Regulatory)

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...

12 Noviembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 Noviembre 2024
Edgar (US Regulatory)

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...

11 Noviembre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.04560.6599704750056.90947.426.732918538976.95107148CS
4-0.445-6.013513513517.47.836.1923703586.95693278CS
120.1952.884615384626.7611.166.1934259498.25784412CS
260.2253.343239227346.7311.165.27527204207.57000461CS
52-2.255-24.48425624329.2114.845.27534033378.2555935CS
1560.3956.021341463416.5623.492.0929760598.10066473CS
2605.085271.925133691.8735.11.625553919.68503925CS

ALT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Altimmune?
El precio actual de las acciones de Altimmune es US$ 6.955
¿Cuántas acciones de Altimmune están en circulación?
Altimmune tiene 71,124,625 acciones en circulación
¿Cuál es la capitalización de mercado de Altimmune?
La capitalización de mercado de Altimmune es USD 497.87M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Altimmune?
Altimmune ha negociado en un rango de US$ 5.275 a US$ 14.84 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Altimmune?
El ratio precio/beneficio de Altimmune es -5.6
¿Cuál es el ratio de efectivo a ventas de Altimmune?
El ratio de efectivo a ventas de Altimmune es 1.16k
¿Cuál es la moneda de reporte de Altimmune?
Altimmune presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Altimmune?
El último ingresos anual de Altimmune es USD 426k
¿Cuál es el último beneficio anual de Altimmune?
El último beneficio anual de Altimmune es USD -88.45M
¿Cuál es la dirección registrada de Altimmune?
La dirección registrada de Altimmune es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Altimmune?
La dirección del sitio web de Altimmune es www.altimmune.com
¿En qué sector industrial opera Altimmune?
Altimmune opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
RNAZTransCode Therapeutics Inc
US$ 14.20
(107.91%)
32.08M
SLXNSilexion Therapeutics Corporation
US$ 1.0547
(81.84%)
189.38M
HEPAHepion Pharmaceuticals Inc
US$ 0.2643
(60.18%)
282.1M
TRIBTrinity Biotech PLC
US$ 1.17
(53.95%)
104.46M
DGNXDiginex Ltd
US$ 13.70
(45.44%)
522.39k
LPTXLeap Therapeutics Inc
US$ 0.66025
(-70.66%)
9.86M
STSSSharps Technology Inc
US$ 0.4469
(-69.39%)
14.63M
TECXTectonic Therapeutic Inc
US$ 18.80
(-54.35%)
374.68k
MGOLMGO Global Inc
US$ 0.1631
(-42.37%)
20.44M
SABSSAB Biotherapeutics Inc
US$ 2.525
(-42.09%)
1.15M
NVDANVIDIA Corporation
US$ 126.06
(6.45%)
388.09M
HEPAHepion Pharmaceuticals Inc
US$ 0.2637
(59.82%)
282.11M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.5429
(31.74%)
224.09M
SLXNSilexion Therapeutics Corporation
US$ 1.055
(81.90%)
189.38M
TRIBTrinity Biotech PLC
US$ 1.17
(53.95%)
104.46M

ALT Discussion

Ver más
Mark102 Mark102 2 meses hace
Still Holding here
As far as buyout and the OS you're looking at roughly 7 billion = 100 a share
10 billion = 140

👍 1
Mark102 Mark102 6 meses hace
As promised I don't see any dilution in the filing. Shorts are in trouble
👍 1
Mark102 Mark102 6 meses hace
Float is Locked and over 23 million naked shares Short. Shorts have failed Miserably at shaking out Retail and can't cover without a massive loss.
Price Targets
Partner 50 to 75
Buyout 140 to 200
👍 1
Mark102 Mark102 6 meses hace
https://forextv.com/top-news/altimmune-announces-publication-of-clinical-study-of-pemvidutide-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-journal-of-hepatology/
👍 1 💯 1
Mark102 Mark102 7 meses hace
IT'S HAPPENING
👍️0
Mark102 Mark102 7 meses hace
Beautiful Bull Flag
👍️0
girlfriend girlfriend 7 meses hace
Well....not quite but a nice pop anyways this week.
👍️0
Mark102 Mark102 7 meses hace
Last chance next week above 20
👍️0
Mark102 Mark102 7 meses hace
It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
👍 1
brfv11 brfv11 8 meses hace
Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
👍 1
Mark102 Mark102 8 meses hace
Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
👍️0
Mark102 Mark102 8 meses hace
Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
👍️0
brfv11 brfv11 8 meses hace
Time to admit shorty got this one right! This one is going all the way down.
Merger/ buyout what a joke.
👍️0
akamaii akamaii 8 meses hace
This Wednesday we hope data rules. Give us data 📈
👍️0
akamaii akamaii 9 meses hace
Going long for a year 75 target or 50 plus
👍️0
Mt. Blanc Mt. Blanc 9 meses hace
So much for my ALT prediction.

The stock slipped to $7 and may be cratering more since it's getting no love.

Maybe ALT is a $5 stock or lower if buyers aren't interested.

mb
👍️0
Mt. Blanc Mt. Blanc 10 meses hace
Radar. ALT $11- $12

Getting picked up.

mb
👍️0
Monksdream Monksdream 10 meses hace
ALT over $10
Next day settlement begins 5/28 per SEC mandate
👍️0
Monksdream Monksdream 10 meses hace
ALT 10Q due 3/27
Next day settlement begins 5/28
👍️0
saigai saigai 10 meses hace
patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
👍️0
Mark102 Mark102 10 meses hace
Buyout? Partnership? In less than 9 trading days we will find out.
👍️0
Mark102 Mark102 11 meses hace
BUCKLE UP. going to break 15 soon
👍️0
saigai saigai 11 meses hace
a good read
https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
👍️0
saigai saigai 11 meses hace
slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
👍️0
Mt. Blanc Mt. Blanc 11 meses hace
ALT @ $12?

Interesting

mb
👍️0
saigai saigai 11 meses hace
institutional ownership from nasdaq site
https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
👍️0
saigai saigai 12 meses hace
big volume wrong direction for now
👍️0
saigai saigai 12 meses hace
a good read
https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
👍️0
saigai saigai 12 meses hace
and a few more...
👍️0
saigai saigai 1 año hace
you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
👍️0
saigai saigai 1 año hace
driving me nutz but i wont sell this until !!!
👍️0
murocman murocman 1 año hace
Post from another board relevant to ALT:

GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
👍️0
AGORDON AGORDON 1 año hace
Altimmune, Inc.
(Nasdaq - ALT) $12/share
Market cap = $644M
Cash = $140M
Cash Burn rate = ($76)/Y
Catalysts:
Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
👍️0
Mark102 Mark102 1 año hace
I was wrong ALT is attending the JPM Let's get this deal done.
👍️0
saigai saigai 1 año hace
thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
👍️0
Mark102 Mark102 1 año hace
Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
Now why is ALT not attending the JPM conference this week? Stay tuned
👍️0
saigai saigai 1 año hace
im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
👍️0
Mark102 Mark102 1 año hace
Float is locked, tutes trying to shake few out but this is a done deal IMO
👍️0
saigai saigai 1 año hace
this is a powder keg...
👍️0
saigai saigai 1 año hace
i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
👍️0
Mark102 Mark102 1 año hace
Been Holding since 6. Buyout or partnership is imminent.
👍️0
1hot toddy 1hot toddy 1 año hace
HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
👍️0
Bud-Wiser Bud-Wiser 1 año hace
Nice comeback today -I’m back in
👍️0
1hot toddy 1hot toddy 1 año hace
WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BABY MONSTER HERE
👍️0
eyeownu eyeownu 1 año hace
got dammmmmmmmmmm. oprah must be buying out the company
👍️0
1hot toddy 1hot toddy 1 año hace
WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
MONSTER WEIGHT LOSS CO HERE
👍️0
Mark102 Mark102 1 año hace
Next Gap to 19 to fill. PT 60 to 100 on a buyout
👍️0
1hot toddy 1hot toddy 1 año hace
WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
👍️0
eyeownu eyeownu 1 año hace
rallys over IMO. end of year.. could be wrong tho!
👍️0
1hot toddy 1hot toddy 1 año hace
WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
👍️0

Su Consulta Reciente

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados